{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:55:02Z","timestamp":1774382102196,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Impot Res"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A retrospective analysis of 186 priapism cases between 2015\u20132024 was conducted using ICD-10 codes (N48.3) in a single high-volume institution. Data on age, race, insurance status, priapism subtype, etiology, and treatment outcomes were collected. The median age at presentation was 50.5 years (IQR: 39.3\u201360.0), with most patients being White (60.2%). Black and Asian patients tended to present at younger ages than White patients (45 and 38 vs. 55.5 years,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Black patients had longer priapism durations than White patients (36 vs. 7.8\u2009h,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Commercial insurance was most common (60.2%), but those with Medi-Cal\/Medicaid or self-pay had longer episodes compared to commercial payers (25 and 39 vs. 7\u2009h, respectively,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). Acute ischemic priapism was the most common subtype (63.4%), with intracavernosal injection therapy (54.8%) as the leading cause followed by medications such as Trazodone. Multivariate analysis revealed that ischemic priapism duration was the strongest predictor of de novo ED, with episodes lasting more than 36\u2009h significantly increasing the risk (OR\u2009=\u200961.3,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), although episodes over 20\u2009h were also found to increase the risk (OR\u2009=\u200925.2,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007). These results emphasize the importance of early intervention and addressing health disparities to reduce long-term complications.\n                  <\/jats:p>","DOI":"10.1038\/s41443-025-01076-9","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T07:31:26Z","timestamp":1745307086000},"page":"23-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk factors, diagnosis, and long-term erectile dysfunction outcomes in priapism: a retrospective analysis of 186 cases from a single institution"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1177-8039","authenticated-orcid":false,"given":"Joseph A.","family":"Borrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3256-7721","authenticated-orcid":false,"given":"Anthony","family":"Bettencourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago P.","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0466-6830","authenticated-orcid":false,"given":"Juan J.","family":"Andino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1852-4833","authenticated-orcid":false,"given":"Sriram V.","family":"Eleswarapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7833-7071","authenticated-orcid":false,"given":"Jesse N.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"1076_CR1","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1097\/JU.0000000000002236","volume":"206","author":"TJ Bivalacqua","year":"2021","unstructured":"Bivalacqua TJ, Allen BK, Brock G, Broderick GA, Kohler TS, Mulhall JP, et al. Acute ischemic priapism: an AUA\/SMSNA guideline. J Urol. 2021;206:1114\u201321.","journal-title":"J Urol"},{"key":"1076_CR2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.21037\/tau-22-180","volume":"11","author":"RJ Howland","year":"2022","unstructured":"Howland RJ, Daignault-Newton S, Blair YA. The 10-year priapism experience: identifying clearer targets for intervention. Transl Androl Urol. 2022;11:1495\u2013502.","journal-title":"Transl Androl Urol"},{"key":"1076_CR3","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1046\/j.1464-410X.2002.03022.x","volume":"90","author":"AB Adeyoju","year":"2002","unstructured":"Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, et al. Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. BJU Int. 2002;90:898\u2013902.","journal-title":"BJU Int"},{"key":"1076_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.4088\/JCP.v62n0510","volume":"62","author":"MT Compton","year":"2001","unstructured":"Compton MT, Miller AH. Priapism associated with conventional and atypical antipsychotic medications: a review. J Clin Psychiatry. 2001;62:362\u20136.","journal-title":"J Clin Psychiatry"},{"key":"1076_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1743-6109.2007.00560.x","volume":"5","author":"F Numan","year":"2008","unstructured":"Numan F, Cantasdemir M, Ozbayrak M, Sanli O, Kadioglu A, Hasanefendioglu A, et al. Posttraumatic nonischemic priapism treated with autologous blood clot embolization. J Sex Med. 2008;5:173\u20139.","journal-title":"J Sex Med"},{"key":"1076_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.acuro.2023.10.006","volume":"48","author":"C Altez-Fernandez","year":"2024","unstructured":"Altez-Fernandez C, Lamas L, Bohorquez M, Chantada V, Ralph D. Cocaine-related ischemic priapism. Systematic review and presentation of a single center series. Actas Urol Esp. 2024;48:281\u20138.","journal-title":"Actas Urol Esp"},{"key":"1076_CR7","doi-asserted-by":"publisher","unstructured":"Moodley D, Badenhorst A, Choonara Y, Adam A. The assessment and aetiology of drug-induced ischaemic priapism. Int J Impot Res. 2024. https:\/\/doi.org\/10.1038\/s41443-024-01006-1.","DOI":"10.1038\/s41443-024-01006-1"},{"key":"1076_CR8","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jsxm.2019.07.024","volume":"16","author":"H Zhao","year":"2019","unstructured":"Zhao H, Berdahl C, Bresee C, Moradzadeh A, Houman J, Kim H, et al. Priapism from recreational intracavernosal injections in a high-risk metropolitan community. J Sex Med. 2019;16:1650\u20134.","journal-title":"J Sex Med"},{"key":"1076_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.amjsurg.2010.03.017","volume":"201","author":"KL Chrouser","year":"2011","unstructured":"Chrouser KL, Ajiboye OB, Oyetunji TA, Chang DC. Priapism in the United States: the changing role of sickle cell disease. Am J Surg. 2011;201:468\u201374.","journal-title":"Am J Surg"},{"key":"1076_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.urology.2021.03.063","volume":"163","author":"PM Patel","year":"2022","unstructured":"Patel PM, Slovacek H, Pahouja G, Patel HD, Cao D, Emerson J, et al. Socioeconomic disparities and risk factors in patients presenting with ischemic priapism: a multi-institutional study. Urology. 2022;163:50\u20135.","journal-title":"Urology"},{"key":"1076_CR11","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/jsxmed\/qdae031","volume":"21","author":"TP Furtado","year":"2024","unstructured":"Furtado TP, Teloken PE, Ortega Y, Narus J, Wolchasty NP, Mulhall JP. Delineating patient errors in an intracavernosal injection program. J Sex Med. 2024;21:529\u201332.","journal-title":"J Sex Med"},{"key":"1076_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4111\/icu.20200195","volume":"62","author":"T Shah","year":"2021","unstructured":"Shah T, Deolanker J, Luu T, Sadeghi-Nejad H. Pretreatment screening and counseling on prolonged erections for patients prescribed trazodone. Investig Clin Urol. 2021;62:85\u20139.","journal-title":"Investig Clin Urol"},{"key":"1076_CR13","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jsxm.2020.05.019","volume":"17","author":"ME Rezaee","year":"2020","unstructured":"Rezaee ME, Gross MS. Are we overstating the risk of priapism with oral phosphodiesterase type 5 inhibitors? J Sex Med. 2020;17:1579\u201382.","journal-title":"J Sex Med"},{"key":"1076_CR14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.sxmr.2020.10.003","volume":"9","author":"T Hwang","year":"2021","unstructured":"Hwang T, Shah T, Sadeghi-Nejad H. A review of antipsychotics and priapism. Sex Med Rev. 2021;9:464\u201371.","journal-title":"Sex Med Rev"},{"key":"1076_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5721","volume":"33","author":"B Abbasi","year":"2024","unstructured":"Abbasi B, Shaw NM, Lui JL, Hakam N, Nabavizadeh B, Breyer BN. Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis. Pharmacoepidemiol Drug Saf. 2024;33:e5721.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1076_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.juro.2018.05.004","volume":"200","author":"AL Burnett","year":"2018","unstructured":"Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200:633\u201341.","journal-title":"J Urol"},{"key":"1076_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/0974-7796.165717","volume":"8","author":"DK Pal","year":"2016","unstructured":"Pal DK, Biswal DK, Ghosh B. Outcome and erectile function following treatment of priapism: an institutional experience. Urol Ann. 2016;8:46\u201350.","journal-title":"Urol Ann"},{"key":"1076_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/sxmrev\/qeae007","volume":"12","author":"M Elmarasi","year":"2024","unstructured":"Elmarasi M, Alsaeedi A, Elmakaty I, Elsayed B, Khalil IA, Aldeeb M, et al. Early vs delayed insertion of penile prosthesis in patients with refractory priapism: a systematic review and meta-analysis. Sex Med Rev. 2024;12:528\u201336.","journal-title":"Sex Med Rev"},{"key":"1076_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.21037\/tau-23-224","volume":"13","author":"DA Velasquez","year":"2024","unstructured":"Velasquez DA, Guimaraes PVB, Lescay H, Raheem O. Penile prosthesis in priapism: a systematic review of outcomes and complications. Transl Androl Urol. 2024;13:574\u201383.","journal-title":"Transl Androl Urol"},{"key":"1076_CR20","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.juro.2010.02.014","volume":"183","author":"EA Salem","year":"2010","unstructured":"Salem EA, El Aasser O. Management of ischemic priapism by penile prosthesis insertion: prevention of distal erosion. J Urol. 2010;183:2300\u20133.","journal-title":"J Urol"},{"key":"1076_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.sxmr.2022.06.007","volume":"10","author":"S Dekalo","year":"2022","unstructured":"Dekalo S, Stern N, Broderick GA, Brock G. Priapism or prolonged erection: is 4\u20136\u2009h of cavernous ischemia the time point of irreversible tissue injury? Sex Med Rev. 2022;10:660\u20138.","journal-title":"Sex Med Rev"},{"key":"1076_CR22","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1097\/MLR.0000000000001010","volume":"57","author":"AJ Mainor","year":"2019","unstructured":"Mainor AJ, Morden NE, Smith J, Tomlin S, Skinner J. ICD-10 Coding will challenge researchers: caution and collaboration may reduce measurement error and improve comparability over time. Med Care. 2019;57:e42\u2013e6.","journal-title":"Med Care"},{"key":"1076_CR23","first-page":"912","volume":"2017","author":"J Horsky","year":"2017","unstructured":"Horsky J, Drucker EA, Ramelson HZ. Accuracy and completeness of clinical coding using ICD-10 for ambulatory visits. AMIA Annu Symp Proc. 2017;2017:912\u201320.","journal-title":"AMIA Annu Symp Proc"}],"container-title":["International Journal of Impotence Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01076-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01076-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01076-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:50:24Z","timestamp":1770025824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41443-025-01076-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1076"],"URL":"https:\/\/doi.org\/10.1038\/s41443-025-01076-9","relation":{},"ISSN":["0955-9930","1476-5489"],"issn-type":[{"value":"0955-9930","type":"print"},{"value":"1476-5489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Ethical approval for this study was obtained from the University of California, Los Angeles Institutional Review Board (IRB), under the protocol number IRB-19-0144. This was a retrospective study utilizing de-identified data, and as such, the requirement for informed consent was waived by the IRB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}